



PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922

PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

ABHA NO

AGE/SEX Female : 34 Years :22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54

REPORTED :22/10/2023 15:20:48

Test Report Status Results Biological Reference Interval Final Units

HAEMATOLOGY - CBC							
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE						
BLOOD COUNTS,EDTA WHOLE BLOOD							
HEMOGLOBIN (HB)	11.9 Low	12.0 - 15.0	g/dL				
METHOD : CYANIDE FREE DETERMINATION RED BLOOD CELL (RBC) COUNT	4.10	3.8 - 4.8	mil/µL				
METHOD: ELECTRICAL IMPEDANCE WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	6.20	4.0 - 10.0	thou/µL				
PLATELET COUNT	251	150 - 410	thou/µL				
METHOD: ELECTRONIC IMPEDANCE							
RBC AND PLATELET INDICES							
HEMATOCRIT (PCV)	37.2	36 - 46	%				
METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	91.0	83 - 101	fL.				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.1	27.0 - 32.0	Pg				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	32.0	31.5 - 34.5	g/dL				
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	14.8 High	11.6 - 14.0	%				
MENTZER INDEX	22.2						
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	9.7	6.8 - 10.9	n.				
WBC DIFFERENTIAL COUNT							
NEUTROPHILS	45	40 - 80	%				
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY LYMPHOCYTES	45 High	20 - 40	%				
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY MONOCYTES	05	2 - 10	96				

Dr. Akansha Jain **Consultant Pathologist**





Page 1 Of 18









REF. DOCTOR: SELF PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

ABHA NO

AGE/SEX : 34 Years Female DRAWN ;22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status <u>Final</u>	Results	Biological Reference Ir	nterval Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	05	1 - 6	96
BASOPHILS	00	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT	2.79	2.0 - 7.0	thou/µL
METHOD : CALCULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT	2.79	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT	0.31	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT	0.31	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1		

Shoot Counts, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) (< 13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thelassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist** Page 2 Of 18













PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251

CLIENT PATIENT ID: 012310220015

ABHA NO

: 34 Years AGE/SEX Female :22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54

REPORTED: 22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 5.2

Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0(ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 102.5

METHOD: CALCULATED PARAMETER

< 116.0

mg/dL

96

Dr. Akansha Jain **Consultant Pathologist**

Page 3 Of 18











PATIENT NAME: DEEPALI KATHURIA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID: : DEEPE221089251 CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female DRAWN ;22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54 REPORTED: 22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

mm at 1 hr E.S.R. 0 - 20

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)*

d>rterpretation(s)</br>
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-
b>Used For</br>

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for wellcontrolled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- eAG (Estimated average glucose) converts percentage HbAIc to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 " HbAIc 46.7

-

 anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilinubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

of New Section of the Section of the Section of the Section of the Section of that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.GRP is superior to ESR because it is more sensitive and reflects a more rapid change.

b>TEST INTERPRETATION

Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocanditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

<br

 salicylates)

REFERENCE:
1. Nethan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition."

Dr. Akansha Jain Consultant Pathologist





Page 4 Of 18







REF. DOCTOR: SELF PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female DRAWN ;22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist** Page 5 Of 18









PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001922
PATIENT ID : DEEPF221089251

CLIENT PATIENT ID: 012310220015

ABHA NO

AGE/SEX : 34 Years Female DRAWN :22/10/2023 09:17:00 RECEIVED :22/10/2023 09:56:54

REPORTED :22/10/2023 15:20:48

Test Report Status	Final	Results	Biolo	gical	Refere	ence l	Interv	al	Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	102 High	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	96	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDL			
CHOLESTEROL, TOTAL	132	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD: CHOLESTEROL OXIDASE TRIGLYCERIDES	91	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD: LIPASE/GPO-PAP NO CORRECTION HDL CHOLESTEROL	39 Low	< 40 Low	mg/dL
TIDE CHOLLSTEROL	55 604	>/=60 High	mg/ ac
METHOD: DIRECT CLEARANCE METHOD CHOLESTEROL LDL	75	< 100 Optimal 100 - 129 Near optimal/ above optin 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL nal
NON HDL CHOLESTEROL	93	Desirable: Less than 130 Above Desirable: 130 - 15 Borderline High: 160 - 18 High: 190 - 219 Very high: > or = 220	

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist





Page 6 Of 18

View Details











PATIENT NAME: DEEPALI KATHURIA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138404 ACCESSION NO: 0251WJ001922 AGE/SEX : 34 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL DRAWN ;22/10/2023 09:17:00 PATIENT ID : DEEPF221089251 F-703, F-703, LADO SARAI, MEHRAULISOUTH CLIENT PATIENT ID: 012310220015 RECEIVED: 22/10/2023 09:56:54 WEST DELHI ABHA NO REPORTED :22/10/2023 15:20:48 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
VERY LOW DENSITY LIPOPROTEIN	18.2	= 30.0 mg/dL</th
CHOL/HDL RATIO	3.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	1.9	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

STORE OF RESIDENCE AND ADDRESS.	TESC TES (THE COSCICIONIC CHI GIOTHICCHII) GI	sensely by empire resourcement or entire			
Risk Category					
Extreme risk group	A.CAD with > 1 feature of high risk group				
	B. CAD with > 1 feature of Very high risk p	group or recurrent ACS (within 1 year) despite LDL-C < or =			
	50 mg/dl or polyvascular disease				
Very High Risk	1. Established ASCVD 2. Diabetes with 2 :	major risk factors or evidence of end organ damage 3.			
	Familial Homozygous Hypercholesterolemi	1			
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ				
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary				
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque				
Moderate Risk	Moderate Risk 2 major ASCVD risk factors				
Low Risk	Low Risk 0-1 major ASCVD risk factors				
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors					
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use					
Family history of premature ASCVD 4. High blood pressure					
5. Low HDL					

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Terret tremement gomes and status in	intimetron time controller trans	rea on the rine thing on	es proposed by and	I III EVEVI
Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 18

View Details

View Report









CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001922
PATIENT ID : DEEPF221089251
CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female DRAWN :22/10/2023 09:17:00 RECEIVED :22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

Extreme Risk Group Category B	<or 30<="" =="" th=""><th><or 60<="" =="" th=""><th>> 30</th><th>>60</th></or></th></or>	<or 60<="" =="" th=""><th>> 30</th><th>>60</th></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.43	0 - 1	mg/dL
METHOD : DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, DIRECT	0.12	0.00 - 0.25	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, INDIRECT	0.31	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	8.1	6.4 - 8.2	g/dL
METHOD: BURET REACTION, END POINT			
ALBUMIN	4.4	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN			
GLOBULIN	3.7	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.2	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE	16	0 - 31	U/L
(AST/SGOT)			
METHOD: TRIS BUFFER NO PSP IFCC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	22	0 - 31	U/L
METHOD: TRIS BUFFER NO PSP IFCC / SPBC 37° C			
ALKALINE PHOSPHATASE	91	39 - 117	U/L
METHOD: AMP OPTIMISED TO IFCC 37° C			
GAMMA GLUTAMYL TRANSFERASE (GGT)	18	7 - 32	U/L
METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IPCC):			
LACTATE DEHYDROGENASE	293	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 8 5.0 - 18.0 mg/dL

METHOD: UREASE KINETIC

Dr. Akansha Jain Consultant Pathologist



Page 8 Of 18

View Details

View Report









CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001922
PATIENT ID: DEEPF221089251
CLIENT PATIENT ID: 012310220015

ABHA NO :

AGE/SEX : 34 Years Female DRAWN :22/10/2023 09:17:00 RECEIVED :22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

CREATININE, SERUM

CREATININE 0.88 0.6 - 1.2 mg/dL

METHOD: ALKALINE PICRATE NO DEPROTEINIZATION

BUN/CREAT RATIO

BUN/CREAT RATIO 9.09

METHOD: CALCULATED PARAMETER.

URIC ACID, SERUM

URIC ACID 5.1 2.4 - 5.7 mg/dL

METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 8.1 6.4 - 8.3 g/dL

METHOD: BLURET REACTION, END POINT

ALBUMIN, SERUM

ALBUMIN 4.4 3.8 - 4.4 g/dL

METHOD: BROMOCRESOL GREEN

GLOBULIN

GLOBULIN 3.7 2.0 - 4.1 g/dL

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain Consultant Pathologist Page 9 Of 18





View Details

View Report









REF. DOCTOR: SELF PATIENT NAME: DEEPALI KATHURIA

ABHA NO

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female :22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

	<u> </u>	i i			
Test Report Status <u>Final</u>	Results	Biological Reference	Biological Reference Interval Units		
SODIUM, SERUM	141.3	137 - 145	mmol/L		
METHOD: ION-SELECTIVE ELECTRODE POTASSIUM, SERUM	4.95	3.6 - 5.0	mmol/L		
METHOD: ION-SELECTIVE ELECTRODE CHLORIDE, SERUM METHOD: ION-SELECTIVE BISCIPLOF	102.4	98 - 107	mmol/L		

Interpretation(s)

Sodium	Potassium	Chloride
Decreased In:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticutarolist, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes wellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhahdismyolysis, acidosis, dehydration, renal failure, Addison's disease, 8TA type 1V, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy [Normal serum chloride]

SLUCOSE FASTING, FLUCRIDE PLASMA-

b> TEST DESCRIPTION


Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in

the urine.

4b-Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

4b-Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugsinsulin, etherol, proprianolol; sulfonylureas, toibutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within inclividuals. Thus, glycosylated hemoglobin(HbAIc) levels are favored to monitor glycemic control.







Page 10 Of 18









CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female DRAWN ;22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc.
GLUCOSE, POST-PRANDIAL, PLASHA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

S a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilinubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.

 bilirubin excretion (eg., obstruction and hepetitis), and abnormal bilirubin metabolism (eg., hereditary and neonatal (aundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepetitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

 relative, hemolytic anemia, pancrest for liver relative. As I levers increase during current of viral negotiate, shocking or the liver anemia, pancresstills, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

<a href="https://dx.edu.org/livers

obstruction, Osteoblastic bone tumors, osteomalocia, hepaticis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Mainutrition, Protein deficiency, Wilsons disease.

Space of the state of t intestine, spicen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billary system and pancreas. Conditions that

has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

<a href="https://br.nib.org/linear-published-liver-p

BLOOD UREA NITROGEN (BUN), SERUM-

Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Fallure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

cb>Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

- kb>Lower than normal level may be due to: </br>

URIC ACID, SERUM-
Causes of Increased levels: -Dietary(High Probein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM_Metabolic syndrome

to > Causes of decreased levels
-Low Zinc intake, OCP_Multiple Scienosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

<br

<br

neprrooc synarome, received re enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,mainutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 11 Of 18







C/O Aakriti Labs Prt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road Jaipur, 302015 Rajasthan, India







REF. DOCTOR: SELF PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female DRAWN ;22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54 REPORTED: 22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE CLEAR.

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

4.7 - 7.55.5

METHOD: DOUBLE INDICATOR PRINCIPLE 1.003 - 1.035 SPECIFIC GRAVITY <=1.005

METHOD: JONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NEGATIVE METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NEGATIVE

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION BLOOD NOT DETECTED NOT DETECTED

METHOD: PEROCIDASE ANTI PEROXIDASE NOT DETECTED NOT DETECTED

BILIRUBIN METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

/HPF NOT DETECTED NOT DETECTED RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 0-5/HPE 1-2 METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain **Consultant Pathologist**



Page 12 Of 18









ABHA NO

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: **0251WJ001922**PATIENT ID: DEEPF221089251
CLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female
DRAWN :22/10/2023 09:17:00
RECEIVED :22/10/2023 09:56:54
REPORTED :22/10/2023 15:20:48

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	0-1	0-5	/HPF
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain Consultant Pathologist Page 13 Of 18





View Details

View Report









CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251

CLIENT PATIENT ID: 012310220015 ABHA NO : AGE/SEX : 34 Years Female
DRAWN :22/10/2023 09:17:00
RECEIVED :22/10/2023 09:56:54
REPORTED :22/10/2023 15:20:48

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 18

View Details

View Report









PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO : **0251WJ001922**PATIENT ID : DEEPF221089251

CLIENT PATIENT ID: 012310220015

ABHA NO

AGE/SEX : 34 Years Female DRAWN :22/10/2023 09:17:00

RECEIVED :22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist



Page 15 Of 18

View Details

View Report









PATIENT NAME: DEEPALI KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPE221089251

PATIENT ID : DEEPF221089251
GLIENT PATIENT ID: 012310220015

ABHA NO

AGE/SEX : 34 Years Female DRAWN :22/10/2023 09:17:00

RECEIVED : 22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD: GROSS EXAMINATION

Dr. Abhishek Sharma Consultant Microbiologist

Page 16 Of 18





View Details

View Report









CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001922 PATIENT ID : DEEPF221089251 CLIENT PATIENT ID: 012310220015

DRAWN

AGE/SEX

: 34 Years Female ;22/10/2023 09:17:00 RECEIVED: 22/10/2023 09:56:54

REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3	99.37	60.0 - 181.0	ng/dL
METHOD: CHEMILUMINESCENCE T4	8.50	4.5 - 10.9	μg/dL
METHOD: CHEMILUMINESCENCE TSH (ULTRASENSITIVE)	3.126	0.550 - 4.780	μIU/mL
METHOD: CHEMILLIMINESCENCE			

Interpretation(s)

Triiodothyronine T3. Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain Consultant Pathologist



Page 17 Of 18









CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001922
PATIENT ID: DEEPF221089251
GLIENT PATIENT ID: 012310220015

AGE/SEX : 34 Years Female DRAWN :22/10/2023 09:17:00 RECEIVED :22/10/2023 09:56:54 REPORTED :22/10/2023 15:20:48

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist Page 18 Of 18 Section in the Page 18 Of 18





View Details

View Benort







Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563

PATIENT: MRS. DEEPALI KATHURIA	AGE &SEX :34Y/F	
REF: BY : MEDI WHEEL	DATE: 22.10.2023	_
	DATE: 22.10.2023	

OPHTHALMIC VISION TESTING

LT.EYE

EYE: RT. EYE

DISTANCE: 6/6 6/6

NEAR: NSVEINES NS

COLOUR VISION: Normal

MS OF A GPTH Dr. RAKESH SHARM



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563

Name : Ms. DEEPALI KATHURIA

Age/Gender: 34 Y/Female Patient ID : 012310220015 BarcodeNo : 10102951

Referred By : Self

Registration No: 68679

Registered : Z

: 22/Oct/2023 09:17AM

Analysed

: 22/Oct/2023 02:10PM

Reported

: 22/Oct/2023 02:10PM

Panel

: ACROFEMI HEALTHCARE LTD (

MEDIWHEEL)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

wellness


*** End Of Report ***

Page 3 of 1



Dr. Neera Mehta M.B.S., D.M.R.D. RMCNO.005807/14853

ALPL policy mandates the film records to be maintained for a period of 3 months only. Kindly collect the films before this period



T 78.00°

R 36.00"

.06

Allengers ECG (Pisces)(PIS218210312)

Axis

-30

180

80 ms 338/342 ms 50.00• 36.00• 78.00•

Vent Rate : 62 bpm PR Interval : 112 ms QRS Duration: 80 ms QT/QTC INT : 338/342 P-QRS-T axis: 50.00*3

Dr. NITIZ GOYAL



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U8\$195RJ2004PTC019563

	ECHOCARI	DIOGRAM RE		1.000.00	
REF BY	MEDI WHEEL	DATE	22/10/2023	REG NO	
NAME	MRS DEEPALI KATHURIA	AGE	34Y	SEX	FEMALE

The second second second second	The second second second second		DDVALVE	mental and a recommendation			OT .	
MITRAL		NORMAL					NORMAL	
AORTIC		NORMAL		PULMONARY	PULMONARY		NORMAL	
2D/M-MOD	Total Car				- Inches			
IVSD mm	7.4		IVSS mm	12.2	AORTA	TA mm 25.0		
LVID mm	45.0		LVIS mm	30.8	LA mm		27.7	
LVPWD mm	7.8		LVPWS mm	12.2	EF%		60%	
CHAMBERS		- 40					-121	
LA		NO	RMAL	RA		NO	RMAL	
LV		NO	RMAL	RV		NO	RMAL	
PERICARDIUM		NO	RMAL					
DOPPLER STU	DY MITRAL			100				
PEAK VELOCITY m/s E/A		0.96	/0.59	PEAK GRADIANT MmHg				
MEAN VELOCITY m/s				MEAN GRA	MEAN GRADIANT MmHg			
MVA cm2 (PLANITMETERY)		Y)		MVA cm2 (MVA cm2 (PHT)			
MR								
AORTIC								
PEAK VELOCITY	m/s	1.28		PEAK GRAD	IANT MmHg			
MEAN VELOCITY m/s				MEAN GRA	DIANT MmH	2		
AR								
TRICUSPID								
PEAK VELOCITY	m/s	0.76	NAZ.	PEAK GRAD	IANT MmHg			
MEAN VELOCITY m/s			VV	MEAN GRADIANT MmHg		3		
TR 7		TRA	CE	PASP mmHg		29+1	RAP	
PULMONARY					1.60			
PEAK VELOCITY	m/s	0.82		PEAK GRAD	IANT MmHg			
MEAN VELOCIT	Y m/s			THE RESIDENCE OF THE PARTY OF T	DIANT MmH			
PR MILD		RVEDP mml	the state of the s					

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- MILD PR
- TRACE TR (PASP=29+RAP mm of Hg)
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: MILD PR. FAIR LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod 'Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

PATIENT NAME: MRS DEEPALI KATHURIA

AGE & SEX: 34Y/Female

REF. BY : MEDIWHEEL HEALTH PKG

DATE: 22/10/2023

USG: WHOLE ABDOMEN (Female)

LIVER : Is normal in size, shape and echogenecity.

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size-

GALL : Is normal in size shape and echotexture Walls are smooth and

BLADDER regular with normal thickness. 15 mm size calculus seen in GB lumen.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.

SPLEEN: Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Right Kidney:-Size: 96 x 40 mm, Left Kidney:-Size: 90 x 41 mm.

Bilateral Kidneys are normal in size, shape and echotexture, corticomedulary differentiation is fair and ratio appears normal.

Pelvi calvoeal system is normal No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

UTERUS: Uterus is anteverted with normal in size shape & echotexture.

Uterine muscular shadows normal echopattern.

Endometrium is normal and centrally placed

No evidence of mass lesion is seen.

ADNEXA : Both the ovaries are normal in size shape and echotexture.

No mass lesion/ polycystic ovarian cyst is seen.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

NO evidence of lymphadenopathy or mass lesion in retroperitoneum.

Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Cholelithiasis.

DR NEERA MEHTA MBBS, DMRD RMCNO.005807/14853